Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up of the most significant developments at this year’s event.
Exclusive live coverage from day five of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod
Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS
Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida
Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.